Skip to main content
 
Stage of development
Analytical and experimental proof of concept (TRL3)

Intellectual property
PCT application filed

Intended collaboration
Licensing and/or co-development

Contact
Ángel Ibáñez
Vice-presidency for Innovation and Transfer
angel.ibanez@csic.es
comercializacion@csic.es

Reference
CSIC/AI/001
Additional information
#Biotechnology #Health #Research tools #Cell line #Screening assay #Molecular and cell biology

In Vitro synthesis of three-dimensional cell spheroids using ultrasound

Method that enables the rapid and homogeneous formation of three-dimensional cell spheroids, facilitating their production through automated systems for biomedical research and pharmaceutical development.

Market need
In the development of new drugs, immunotherapies, and personalized treatments, there is a growing need for 3D cell models that accurately mimic physiological conditions. Cell spheroids—multicellular microstructures that replicate key tissue features such as gradients, cell–cell interactions, and tumor microarchitecture—are among the most promising tools. However, their generation remains a critical bottleneck, limiting efficient and consistent production across research settings and creating a gap between demand and practical capability.

Proposed solution
This ultrasound-based method enables the rapid and controlled formation of cell spheroids from suspended cells. By applying high-frequency ultrasonic waves, it generates microcurrents and pressure gradients that promote natural cell aggregation, resulting in compact and homogeneous spheroids within minutes. It avoids the need for artificial matrices or complex handling, significantly reducing culture time, experimental costs, and variability. The system also allows precise adjustment of key parameters such as frequency, power, and duration.

Competitive advantages
  • Rapid spheroid generation in minutes, without prolonged culture times.
  • High reproducibility and precise control over spheroid size and density.
  • Automation-compatible and scalable for high-throughput production.
  • Significant reduction in experimental costs and waste.